Use of class I histone deacetylase inhibitor romidepsin in combination regimens

Histone deacetylase (HDAC) inhibitors are epigenetic-modifying agents that have shown promise as anticancer therapies. Several HDAC inhibitors have been approved by the US Food and Drug Administration (FDA) as single-agent therapies to treat T-cell lymphoma. The synergistic combination of HDAC inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrich, Adam, Nabhan, Chadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950458/
https://www.ncbi.nlm.nih.gov/pubmed/27118119
http://dx.doi.org/10.3109/10428194.2016.1160082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950458/
https://www.ncbi.nlm.nih.gov/pubmed/27118119
http://dx.doi.org/10.3109/10428194.2016.1160082

Ejemplares similares